Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein

Molecular Therapy

Volumn 16, Issue 12, 2008, Pages 1919-1926

  Bremer, Edwin ^a,b   van Dam, Gooitzen M ^c   de Bruyn, Marco ^a   van Riezen, Manon ^a   Dijkstra, Marike ^c   Kamps, Gera ^c   Helfrich, Wijnand ^a   Haisma, Hidde ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; KIDNEY CARCINOMA; LIVER TOXICITY; MOUSE; NONHUMAN; NUDE MOUSE; SYSTEMIC THERAPY; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; MUS;

EID: 56749164942     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.203     Document Type: Article

References (31)

1. Yee, D, McGuire, SE, Brunner, N, Kozelsky, TW, Allred, DC, Chen, SH et al. (1996). Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 7: 1251-1257.
2. Brand, K, Arnold, W, Bartels, T, Lieber, A, Kay, MA, Strauss, M et al. (11997), Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 4: 9-16.
3. Glasgow, JN, Everts, M and Curiel, DT (2006). Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 13: 830-844.
4. Li, HJ, Everts, M, Pereboeva, L, Komarova, S, Idan, A, Curiel, DT et al. (2007). Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 67: 5354-5361.
5. Wiley, SR, Schooley, K, Smolak, PJ, Din, WS, Huang, CP, Nicholl, JK et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
6. Pitti, RM, Marsters, SA, Ruppert, S, Donahue, CJ, Moore, A and Ashkenazi, A (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690.
7. Ashkenazi, A, Pai, RC, Fong, S, Lawrence, DA, Marsters, SA et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
8. Roth, W, Isenmann S, Naumann, U, Kugler, S, Bahr, M, Dichgans, J et al. (1999). Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 265: 479-483.
9. Walczak, H, Miller, RE, Ariail, K, Gliniak, B, Griffith, TS, Kubin, M et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
10. Herbst RS, Mendolson, DS, Ebbinghaus, S, Gordon, MS, O'Dwyer, P, Lieberman, G et al. (2006). A phase 1 safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol (Meeting Abstracts) 24: 3013
11. Truneh, A, Sharma, S, Silverman, C, Khandekar, S, Reddy, MP, Deen, KC et al. (2000). Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275: 23319-23325.
12. Muhlenbeck, F, Schneider, P, Bodmer, JL, Schwenzer, R, Hauser, A, Schubert, G et al. (2000). The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAILR1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 275: 32208-32213.
13. Wajant, H, Moosmayer, D, Wuest, T, Bartke, T, Gerlach, E, Schonherr, U et al. (2001). Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20: 4101-4106.
14. Bremer, E, van Dam, G, Kroesen, BJ, de Leij, L and Helfrich, W (2006). Targeted induction of apoptosis for cancer therapy: Current progress and prospects. Trends Mol Med 12: 382-393.
15. Bremer, E, Samplonius, DF, Peipp, M, van Genne, L, Kroesen, BJ, Fey, GH et al. (2005). Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65: 3380-3388.
16. Bremer, E, Samplonius, DF, van Genne, L, Dijkstra, MH, Kroesen, BJ, de Leij, LF et al. (2005). Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280: 10025-10033.
17. Bremer, E, Samplonius, D, Kroesen, BJ, van Genne, L, de Leij, L and Helfrich, W (2004). Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 6: 636-645.
18. Bremer, E, Kuijlen, J, Samplonius, D, Walczak, H, de Leij, L and Helfrich, W (2004). Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109: 281-290.
19. Stieglmaier, J, Bremer, E, Kellner, C, Liebig, TM, ten Cate, B, Peipp, M et al. (2007). Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 57: 233-246.
20. Herraiz, M, Beraza, N, Solano, A, Sangro, B, Montoya, J, Qian, C et al. (2003). Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther 14 463-472.
21. Friedlos, F, Davies, L, Scanlon, I, Ogilvie, LM, Martin, J, Stribbling, SM et al. (2002). Three new prodrugs for suicide gene therapy using carboxypeptidase G2 Elicit bystander efficacy in two xenograft models. Cancer Res 62: 1724-1729.
22. Asklund, T, Appelskog, IB, Ammerpohl, O, Langmoen, IA, Dilber, MS, Aints, A et al. (2003). Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res 284: 183-193.
23. Tao, N, Gao, GP, Parr, M, Johnston, J, Baradet, T, Wilson, JM et al. (2001). Sequestration of adenoviral vector by kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3 28-35.
24. Haisma, HJ, Grill, J, Curiel, DT, Hoogeland, S, van Beusechem, V, Pinedo, HM et al. (2000). Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 7: 901-904.
25. Bergers, G and Benjamin, LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
26. Heideman, DA, Snijders, PJ, Craanen, ME, Bloemena, E, Meijer, CJ, Meuwissen, SG et al. (2001). Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 8: 342-351.
27. Liu, X, Yue, P, Chen, S, Hu, L, Lonial, S, Khuri, FR et al. (2007). The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 67: 4981-4988.
28. Fan, S, Maguire, CA, Ramirez, SH, Bradel-Tretheway, B, Sapinoro, R, Sui, Z et al. (2005). Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 125: 23-33.
29. Inoue, H, Shiraki, K, Ohmori, S, Sakai, T, Deguchi, M, Yamanaka, T et al. (2002). Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int J Mol Med 9: 521-525.
30. He, TC, Zhou, S, da Costa, LT, Yu, J, Kinzler, KW and Vogelstein, B (1998). A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514.
31. Alemany, R and Curiel, DT (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8 1347-1353.